Weakness in this Healthcare Giant is an Opportunity

The pullback was an overreaction [Morning Watchlist] You are receiving this email because you are subscribed to Behind the Markets. If you no longer wish to receive these emails, please [unsubscribe]( here.  Prefer to view this content on our website? [Click here.]( --------------------------------------------------------------- Dear Fellow Investor, Company: ResMed (SYM: RMD) Weakness is an opportunity with ResMed (SYM: RMD). Over the last few weeks, ResMed, which makes masks and continuous-positive-airway-pressure (CPAP) machines, gapped from about $215 to about $180. All after Eli Lilly said its Zepbound weight loss drug helped to reduce the severity of obstructive sleep apnea. --------------------------------------------------------------- Crypto 101 [Retire Faster with This Crypto Blueprint]( [bitcoin]( The Bitcoin halving is triggering a new bull run. And history shows certain altcoins could soar 10,000%+. Get the blueprint we made to ride this wave now. [Get the New Crypto Retirement Blueprint Now]( --------------------------------------------------------------- However, according to a Barron’s report, “Only a few hundred thousand will stop using them, and perhaps a few thousand more that might have been diagnosed with OSA—and used the company’s flow generators—won’t because of the drugs.” If that’s the case, Needham analysts say RMD would lose about $37 million in 2024 revenue, which is less than 1% of estimates of $4.8 billion in 2024 sales. In short, the pullback was an overreaction. --------------------------------------------------------------- Trading Tips [10 AI Stocks Set to Skyrocket – Free Report Inside](Are you ready to seize the opportunity in the booming AI market? Our experts have meticulously identified the 10 best AI stocks to buy now, and we want to share this valuable insight with you – for free! [Click here to download your free report now]( (By clicking this link you agree to receive emails from Trading Tips and it's affiliates. You can opt out at any time) --------------------------------------------------------------- We also have to consider that even though millions may be on the weight loss drugs now, they may not choose to use them long term. In addition, as also noted by Barron’s, “ResMed also has room for considerable growth. Almost a billion people worldwide have mild to severe OSA, according to the National Council on Aging. The company currently treats tens of millions of them, so there are plenty of new patients for the company to serve in the future.” With that, investors may want to use RMD weakness as a buy opportunity. --------------------------------------------------------------- Oxford Club [Man Who Called Nvidia at $1.10: THIS NEW STOCK is the Next Trillion Dollar Company](Biggest Tech Firms in the World are Loading Up! And Apple Just Signed a Deal Through 2040. [Get the Whole Story Here.]( --------------------------------------------------------------- [Join Daily Guru Trades!]( Want more free daily trades in your inbox? [Sign up for Dylan Jovine's Daily Guru Trades Today.]( Do you have your eye on any under-the-radar stock buying opportunities we might have missed? Hit "reply" to this email and let us know! Our mailing address is: Behind the Markets, LLC 4260 NW 1st Avenue, Suite 55 Boca Raton, FL 33431 Copyright © 2024 Behind the Markets, LLC, All rights reserved. You're receiving this email as part of your subscription to Behind the Markets. For more information about our privacy practices, please review our [Privacy Policy]( or our [Legal Notices.]( [Behind the Markets](  [Unsubscribe]( Â